National Science Foundation

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

LiteraSeed operates a clinically validated digital health platform designed to enhance communication between healthcare providers and low health literate patient populations. The platform addresses significant challenges faced by public health providers, particularly in serving patients who may not speak English or have other communication barriers. By enabling these individuals to accurately and remotely self-report symptoms, LiteraSeed aims to prevent costly misdiagnoses, adverse events, and unnecessary emergency room admissions. This approach not only improves access to care for disadvantaged patients but also makes clinical encounters more productive, fostering better understanding of health status and overall patient outcomes.

Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.

The Wistar Institute is the first independent institution in the United States dedicated to medical research and training, recognized for its significant contributions to biomedical science. Originally established as an anatomical teaching museum, it has transformed into a leading center for basic biomedical research and was designated a National Cancer Institute Cancer Center in 1972. The institute specializes in research areas including immunology, infectious diseases, and vaccine development. Its groundbreaking discoveries have facilitated the creation of vaccines for diseases such as rabies, rubella, and rotavirus, as well as the identification of genes linked to various cancers, including breast, lung, and prostate cancer. Additionally, Wistar has played a crucial role in advancing monoclonal antibodies and other vital research technologies, fostering a collaborative environment aimed at addressing critical health challenges.

Amplified Sciences LLC is a molecular diagnostics company focused on the early detection of debilitating diseases, particularly pancreatic cancer and kidney disease. Utilizing an ultra-sensitive molecular sensing technology licensed from Purdue University, the company’s platform can detect disease markers at the single molecule level, enabling accurate diagnosis from bodily fluids such as urine and saliva. This versatile technology is designed for scalability to point-of-care applications, allowing for effective disease screening with a favorable cost structure. Amplified Sciences has developed a working prototype and has published proof of concept data, positioning itself to meet significant unmet medical needs in diagnostics. Founded in 2016 and based in West Lafayette, Indiana, the company was previously known as Nutrabiotix.

Astria Biosciences, based in Pittsburgh, specializes in developing innovative diagnostic and therapeutic solutions for cerebrovascular diseases. The company focuses on addressing neurosurgical challenges through molecular biology, advanced analytics, and small-molecule inhibitors, aiming to provide non-surgical alternatives for neurovascular conditions where surgery is currently the primary option.

CenSyn is a brain health screening platform focused on enhancing the accessibility and efficiency of diagnosing various neurological conditions. The company has developed a handheld EEG monitoring device aimed at accelerating the screening process for Alzheimer's, traumatic brain injury, and epilepsy. Their proprietary software facilitates long-term management of brain health by allowing clinicians to wirelessly monitor and record brain electrical activity in real time. This innovative approach enables the rapid detection of altered mental status, supporting timely diagnosis and immediate treatment, ultimately reducing inpatient costs and improving care for diverse patient populations.

Avisi Technologies Inc. is a company based in Philadelphia, Pennsylvania, that focuses on developing innovative solutions for glaucoma treatment. Founded in 2017, the company has created VisiPlate, a next-generation aqueous shunt that utilizes nanotechnology to provide a defense against blindness caused by glaucoma. This advanced technology aims to improve the effectiveness of glaucoma treatments and enhance patient outcomes.

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

Case Western Reserve University (CWRU) is a private research university located in Cleveland's University Circle. Established in 1843, it comprises various schools including Medicine, Law, Engineering, Arts and Sciences, Nursing, Social Sciences, Dental Medicine, Management, and Mandel School of Applied Social Sciences. CWRU is renowned for its biomedical discoveries, medical education, and top-ranked programs such as international law, health law, and intellectual property law. It offers practical experiences like real-client work and full-time practice experiences to students across various disciplines. The university is accredited by several professional associations and holds membership in the Association of American Universities.

Malcova is an early-stage medical device startup focused on developing advanced imaging solutions for the detection and diagnosis of breast cancer, particularly in women with dense breast tissue. The company employs its proprietary Narrow-Beam Computed Tomography technology, which enhances the effectiveness of medical imaging compared to traditional methods like mammography and tomosynthesis. Additionally, Malcova integrates artificial intelligence in its software to improve the functionality of its devices. The aim is to provide clinicians with tools that facilitate accurate diagnosis while ensuring that the imaging process is safe, comfortable, and accessible for patients. Through these innovations, Malcova seeks to enhance the overall experience and outcomes for breast cancer detection and treatment.

ProMedix is a medical device startup founded in 2019 and headquartered in Portland, Oregon. The company specializes in developing noninvasive, fingertip patient monitors aimed at enhancing the recognition of circulatory dysfunction. Its innovative devices facilitate diagnostic evaluations and the monitoring of therapeutic interventions for various medical conditions, such as trauma, dehydration, and sepsis. By improving home patient monitoring, ProMedix enables physicians to streamline care in both home and critical settings, thereby preventing unnecessary acute visits and enhancing emergency or critical care outcomes.

Metfora is focused on developing a blood test designed to identify chronic lung and heart disorders, as well as cancers, in their early stages. The company employs artificial intelligence to analyze patterns in circulating metabolites within a patient's blood, enabling the detection of diseases that may not present significant symptoms initially. This innovative approach aims to assist both doctors and patients by providing timely insights for diagnosing serious health conditions, ultimately enhancing early intervention and treatment options.

Moshion is a technology company specializing in healthcare workflow optimization, specifically targeting the nursing shortage. It employs 3D image sensors, preserving patient privacy, to gather movement data, which is then analyzed using machine learning models. Moshion's primary focus is to prevent pressure injuries in bedridden patients by monitoring and optimizing patient turning protocols. The platform tracks adherence to these protocols, provides personalized turn schedules, sends reminders to nurses, and automates documentation. This data-driven approach aims to enhance patient care, improve nursing efficiency, and reduce the risk of life-threatening events.

OmniVis is a biotechnology company that has created an integrated portable platform for the detection of pathogens in various environments, including food processing facilities. The company offers a handheld device that quantitatively measures pathogens, providing accurate results in under 30 minutes. This technology utilizes single-use disposable test kits that analyze swabs or liquid samples, significantly reducing the time and labor associated with traditional lab testing. By delivering a low-cost and user-friendly solution, OmniVis enables health organizations to enhance their pathogen detection capabilities effectively.

Atom Bioworks focuses on developing a pattern-recognition enabled platform that combines DNA, antibody mimics, and advanced computational techniques for the detection and treatment of infectious diseases and cancer. The platform utilizes computational biology, quantum chemistry, software, and machine learning to identify specific surface protein patterns associated with diseases. By creating corresponding pattern-matching constructs, Atom Bioworks aims to enhance researchers' capabilities in early diagnosis and therapeutic interventions, ultimately improving medical applications in the fight against infectious diseases and cancer.

CPR Therapeutics is a medical device company focused on developing an advanced automated system for cardiopulmonary resuscitation (CPR). This next-generation technology integrates multiple innovations into a single, easy-to-use system designed for emergency situations. The automated CPR system enhances blood flow and the effectiveness of electrical countershocks, achieving results that were previously only possible in laboratory environments. By combining chest compressions with artificial ventilation, the system aims to preserve brain function and restore spontaneous blood circulation and breathing in individuals experiencing cardiac arrest. This technology represents a significant advancement in emergency medical care, with the potential to improve survival rates in critical situations.

Scopi Medical is a healthcare technology company specializing in next-generation medical optical imaging. It provides a hardware platform and advanced AI/ML software to enable accurate, early detection and interpretation of conditions, directly at primary care clinics. The company's innovative technology allows practitioners, with the aid of remote specialists, to visualize and treat areas of concern, such as chronic nasal conditions like rhinosinusitis, safely and efficiently.

Claria Medical is a pre-commercial medical device start-up focused on developing innovative solutions for women's healthcare, specifically targeting unmet needs in gynecologic surgery. The company specializes in creating minimally invasive surgical tools designed to enhance procedures such as hysterectomy and myomectomy. Claria Medical has received recognition for its early achievements, including a “Safer Technologies Designation” from the U.S. Food and Drug Administration. Additionally, the company has secured funding through private investments as well as grants from the National Science Foundation and the National Institutes of Health to support its product development efforts. By providing specialized surgical assistance, Claria Medical aims to improve outcomes for women undergoing these procedures.

CardioPhi, a Harvard Innovation Labs company, specializes in developing artificial intelligence solutions for the automatic and reliable interpretation of electrocardiograms (ECGs). Their primary goal is to enhance outcomes for individuals with cardiac arrhythmias and decrease public expenditure on cardiovascular diseases, thereby aiding clinicians in assessing heart functionality more effectively.

BrilliantMD specializes in claims management services tailored for the healthcare sector, focusing on enhancing transparency in healthcare data and the claims process. The company has developed a software solution that addresses issues related to claims denials by leveraging advanced technologies such as artificial intelligence, machine learning, and blockchain. This innovative approach aims to provide users with valuable insights and data-driven decision-making capabilities, ultimately helping healthcare organizations improve revenue and streamline their operations.

ControlPoint is an animal diagnostics company dedicated to enhancing animal health and wellness. The company specializes in developing rapid testing methods for multiple pathogens, which aids veterinarians in diagnosing specific conditions, such as those related to kennel cough and other canine respiratory diseases. By providing quick and reliable test results, ControlPoint enables veterinarians to make informed decisions and allows pet owners to spend more quality time with their animals. The focus on improving accessibility and efficiency in diagnostics positions ControlPoint as a key player in the veterinary health sector.

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

Oxalo Therapeutics is focused on developing innovative drug therapies aimed at treating rare kidney diseases and preventing recurring kidney stones. The company specifically targets primary hyperoxaluria and other oxalate-related pathologies through a novel approach that utilizes a gut bacterium to facilitate the safe removal of oxalate from the body. By mimicking natural mechanisms, Oxalo Therapeutics seeks to provide effective treatment options for patients suffering from conditions associated with high levels of oxalate, thereby improving their quality of life and reducing the incidence of kidney stone recurrence. The company's expertise in the microbiome and translational research underpins its commitment to advancing early-stage technology in the field of kidney health.

Aqua Science offers a global platform of technologies and fast and reliable solutions for the testing and treatment of water. They provide research and development, custom reagent and kit manufacture, product assembly, lyophilization services, and contract manufacturing services.

AmCyt is focused on enhancing the efficiency of pathological analysis through a rapid onsite diagnostic device. This technology aims to improve the efficacy of biopsies while addressing labor shortages in clinics and hospitals. By allowing for real-time microscopic evaluation of tissue samples, AmCyt's device reduces the need for additional sampling and minimizes the risk of complications during procedures. Ultimately, this innovation supports healthcare providers in achieving better patient outcomes while conserving time, money, and resources.

Ai-Ris offers automated retinal examinations for primary care. Their retinal imaging system allows general practitioners to screen for diabetic retinopathy without the presence of a specialist. This system consists of a portable headset that uses machine learning algorithms to classify images of the retina of patients without dilating their pupils.

Secure Food Solutions, Inc. is a food safety company based in Martin, Tennessee, established in 2014. The company specializes in developing advanced technologies for the rapid detection of toxins, pathogens, and other contaminants in the global food supply. Among its notable innovations is a patented hyperspectral imaging technology specifically designed to identify corn contaminated with aflatoxin. Additionally, Secure Food Solutions offers rapid microbial tests that monitor and enumerate dangerous pathogens throughout the food and water supply chains. These diagnostic tools enable clients to enhance their food safety programs and mitigate the public health risks associated with foodborne illnesses and outbreaks, all while maintaining affordability.

RaySecur Inc., based in Cambridge, Massachusetts, develops advanced 3D package scanning and imaging devices designed to detect concealed threats, including powders, solids, liquids, and chemical, biological, radiological, and explosive materials. Founded in 2018, the company offers the MailSecur system, which utilizes innovative millimeter-wave technology to provide real-time imaging and threat detection that surpasses traditional X-ray systems. RaySecur’s portable and easy-to-use devices require minimal training for mail screening and can fit in small mailrooms without the need for secure screening areas. Their technology is capable of identifying tiny quantities of substances, making it suitable for use by Fortune 500 companies and government organizations worldwide, ensuring the safety of personnel and critical assets.

Lura Health has developed a groundbreaking non-invasive health monitoring platform that utilizes saliva as a diagnostic fluid, aiming to enhance clinical outcomes in chronic disease management. Founded in 2017 and based in Cambridge, Massachusetts, the company targets various chronic disease markets, including heart disease, chronic kidney disease, diabetes, and tooth decay. Its innovative sensors are integrated into patient-friendly orthodontic devices such as removable retainers and fixed braces. These sensors continuously measure analytes in saliva and automatically transmit data to a smartphone application, allowing users to track key diagnostic metrics related to their oral health. By enabling individuals to monitor their health in real-time, Lura Health seeks to improve personal health management and empower users to take charge of their well-being.

UCHU Biosensors develops a platform of tooth mounted sensors to effortlessly track health through saliva.

Taurus Diagnostics is a health-tech company focused on enhancing the diagnostic process for men suspected of having prostate cancer. The company employs data-centric artificial intelligence solutions to improve the accuracy of magnetic resonance imaging (MRI), which helps prevent unnecessary biopsies. Its AI algorithm has been trained on a vast dataset of patient examples to reliably detect lesions indicative of prostate cancer. This technology allows physicians to identify patients who require biopsies more effectively and provides precise locations of the detected lesions, thereby supporting better clinical decision-making.

Isolere Bio is a biotechnology company dedicated to simplifying the purification of biotherapeutics, particularly monoclonal antibodies and Adeno-Associated Viruses (AAV). Co-founded with the aim of enhancing global access to essential drugs, Isolere Bio develops innovative manufacturing technologies that utilize a straightforward Tangential Flow Filtration (TFF) setup. This approach facilitates a seamless transition from laboratory-scale processes to large-scale industrial production, thereby improving efficiency within the bioprocessing industry. As monoclonal antibodies continue to gain prominence as effective therapeutics and important research tools, Isolere Bio's work plays a crucial role in advancing the development of new diagnostics and treatments.

SafeBVM is a medical device company focused on enhancing patient safety during manual ventilation. Its flagship product, Sotair, is designed to mitigate the risks associated with excessive ventilation, which can lead to complications such as stomach insufflation and acute respiratory distress syndrome. The device employs a flow-blocking and pressure-control valve mechanism that regulates airflow and ensures optimal ventilation parameters based on individual patient needs, including airway resistance and lung compliance. By addressing the issue of inadvertent hyperventilation, SafeBVM aims to improve the safety and effectiveness of manual resuscitation techniques used by healthcare providers.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

Auctus Biologics is a pre-clinical biotechnology company focused on developing antibody mimetics for therapeutic and diagnostic uses. By engineering a ribose-binding protein, the company aims to create a scaffold that binds clinical targets with an affinity comparable to monoclonal antibodies while addressing the limitations associated with traditional antibodies. These limitations include instability and the need for costly cold-chain logistics, which can hinder their effectiveness in extreme environments such as the gastrointestinal tract. Auctus Biologics' innovative approach allows for treatments that are not only more resilient, capable of withstanding conditions like repeated boiling cycles, but also more accessible and cost-effective for patients. This advancement may significantly enhance the delivery of advanced medical therapies.

Alienbyte specializes in providing medical images and corresponding labels essential for the advanced analysis of human and animal anatomy, as well as for training artificial intelligence algorithms. The company has developed a web application that features a user-friendly interface and tools for annotating three-dimensional tomographic images. By incorporating artificial intelligence and algorithmic techniques, Alienbyte enhances the efficiency of the labeling process, thereby increasing the utility of medical images for researchers, healthcare professionals, and patients. This focus on innovative labeling solutions positions Alienbyte as a valuable resource in the medical imaging field.

Reselute is a medical technology company focused on addressing orthopedic implant-related infections. The company specializes in designing, developing, and validating innovative orthopedic spacers that serve as a treatment solution. By leveraging advanced technologies, Reselute aims to enhance the efficiency of medical treatments and improve patient care, ultimately assisting healthcare providers in delivering timely and effective interventions for their patients.

Bired Imaging specializes in infrared imaging technology aimed at enhancing breast cancer detection and localization, particularly in patients with dense breast tissue. Their medical imaging platform employs thermography and a proprietary computerized detection algorithm, which allows for the accurate identification of tumor size and location. This innovative approach enables healthcare professionals to detect high-risk patients at earlier stages, improving screening efficacy while also being cost-effective. Bired Imaging's solutions serve as an important adjunctive technology in breast cancer screening, contributing to more precise diagnostic processes.

PZA Innovation is a biotechnology company focused on developing a reliable testing method for pyrazinamide, a first-line drug used in tuberculosis treatment. The company employs reverse engineering techniques to determine the specific conditions under which pyrazinamide is effective in vitro, thereby enhancing its action against mycobacterium tuberculosis in a living host. By improving the understanding of pyrazinamide susceptibility, PZA Innovation aims to enable healthcare professionals to offer a next-generation treatment that could potentially shorten the duration of tuberculosis therapy for patients.

IntuiTap Medical, established in 2016 and based in Houston, Texas, specializes in manufacturing innovative medical devices. Its flagship product is a handheld device designed to enhance the precision and efficiency of spinal punctures, such as lumbar punctures, spinal anesthesia, and epidurals. This device, the first of its kind, integrates imaging technology with needle guidance and analytics, aiming to eliminate the guesswork, frustration, and pain traditionally associated with these procedures. By improving accuracy and efficiency, IntuiTap's solution aims to reduce procedural costs and instill confidence in both clinicians and patients.

Nanopath Inc. is a molecular diagnostics company focused on enhancing women's health through rapid and precise testing. By utilizing advancements in bioengineering and nanotechnology, the company specializes in the sensitive detection of viral, bacterial, and fungal pathogens without relying on nucleic acid amplification techniques. This innovative approach allows for the delivery of granular and clinically actionable information, thereby improving traditional testing methodologies and enabling healthcare providers to make informed decisions more swiftly.

Quadralynx specializes in the development of wearable biometric devices tailored for adults experiencing motor speech disorders, particularly those who face challenges with volume control due to Parkinson's disease and similar neurological conditions. The company's innovative device employs biofeedback technology to alert users through vibrations when their voice reaches a pathological state. By focusing on speech and voice improvement, Quadralynx aims to enhance the quality of life for individuals affected by these disorders.

Astek Diagnostics is focused on developing a precision diagnostic platform that assists physicians in prescribing appropriate antibiotics for patients suffering from bacterial sepsis within one hour. The company’s technology utilizes a single-use cartridge to rapidly detect bacterial infections in urine by measuring the oxygen consumption of various bacterial species. This innovative approach not only speeds up the identification process but also aids in combating antibiotic resistance through effective susceptibility testing.

Echowear is a company focused on enhancing healthcare access through an innovative smartwatch-based system. This system is designed to facilitate meaningful interactions between patients and care teams, ultimately creating actionable digital health services. Echowear's approach aims to provide users with age-friendly health technologies, allowing for a more inclusive and effective healthcare experience. By leveraging digital solutions, the company seeks to improve patient engagement and streamline communication within the healthcare ecosystem.

ExciPlex specializes in developing diagnostic systems for the detection of mycotoxins in animal feed and feed inputs. The company has created a portable spectrometer that can operate with both cloud-based and offline processing capabilities. This device allows for on-site detection of toxin levels in various types of feed, including grains, finished feeds, silages, and forages. By utilizing photochemical techniques, ExciPlex's technology provides real-time quantification of mycotoxins, enabling farmers to achieve comprehensive traceability throughout the feed production chain. This innovation aims to help prevent the adverse impacts of mycotoxins on animal health and productivity.

Pragma Health provides digital healthcare services. They permit users to perform different tests for cardiovascular, hematology, infectious diseases, and others in the privacy of their home and provide accurate, immediate results, enabling them to get a convenient, cost-effective, and accurate healthcare testing process.

Spekciton Biosciences specializes in biophotonic measurement systems and services aimed at enhancing agricultural performance and sustainability. The company develops innovative technologies that enable the rapid and precise detection of plant stress and viability, providing farmers with essential insights for improving crop management. Additionally, Spekciton offers biosensors designed to quickly identify soil and water contamination, supporting environmental health and agricultural productivity. Through its advanced measurement solutions, the company contributes to a better understanding of bioprocesses, ultimately aiding in the cultivation of resilient and sustainable crops.

The Wrightguard specializes in the development of innovative smart mouthguards tailored for athletes. These mouthguards are equipped with advanced sensors and wireless communication technology that gather real-time biometric data, enabling the monitoring of both health and performance. This technology aims to enhance athlete safety by ensuring consistent placement and uniform thickness of shock-absorbing materials, providing effective protection during sports activities. Wrightguard's products offer an affordable dental solution, making it easier for athletes to prioritize their safety while competing.

Envivo Bio develops a non-invasive device that collects microbiome samples from all regions of the human gastrointestinal tract. The company is based in San Carlos, California.

Clairways specializes in smart lung monitoring technology designed for pharmaceutical clinical trials. The company develops a wearable digital lung monitor that captures critical respiratory metrics for individuals suffering from conditions such as asthma, chronic obstructive pulmonary disease (COPD), and cystic fibrosis (CF). Fitted to the body, this device employs acoustic sensors and machine learning technology to detect and characterize various respiratory metrics. The collected data is presented in an accessible format, allowing healthcare providers to easily monitor and assess patients' respiratory health over the long term.

Lelantos is innovating the gas sensing industry by creating advanced IoT-compatible gas sensors designed for various monitoring applications, including threat detection, industrial safety, environmental and air quality monitoring, and medical diagnostics. The company utilizes micro-electromechanical systems (MEMS) resonator arrays integrated into conventional silicon microchips, resulting in sensors that are miniature, low-power, and cost-effective while delivering superior detection performance compared to existing technologies. Lelantos aims to enhance safety, cleanliness, and health for current and future generations through its cutting-edge solutions.

Biochip Labs, founded in 2019 and headquartered in Cleveland, Ohio, specializes in laboratory testing services for blood disorders, particularly sickle cell disease and thalassemia. The company offers a variety of proprietary microfluidic biomarker assays that assess blood cell adhesion, red blood cell deformability, whole blood rheology, and endothelialized microfluidics. These assays are designed to evaluate the efficacy of emerging targeted and curative therapies, allowing clinicians to effectively monitor patient responses to treatment. By focusing on accurate and high-quality testing, Biochip Labs aims to advance the understanding and management of blood disorders.

Niche Biomedical is a platform and therapy development firm that specializes in creating innovative solutions for chronic injuries and disorders that have not responded to traditional pharmacological treatments. The company has developed ANEUVO®, which focuses on addressing these challenging medical conditions. Among its notable innovations is ExaStim®, a non-invasive neuromodulation system that has received FDA Breakthrough Device Designation for the treatment of spinal cord injuries. Additionally, Niche Biomedical is advancing a gastrointestinal therapeutic device aimed at alleviating postoperative ileus and restoring gastrointestinal motility. This device leverages bioelectronic medicine to revolutionize treatment options for various diseases and injuries that are difficult to manage with conventional pharmaceuticals. The company is also capable of developing miniaturized implantable devices that maintain sophisticated functionality, allowing for targeted neuromodulation therapies.

NanoSpy, Inc., founded in 2017, specializes in rapid pathogen detection through advanced biosensor technology. The company has developed proprietary and patent-pending biosensors that enable the detection of targeted pathogens with high sensitivity and specificity. These biosensors can identify live bacteria at concentrations as low as 5 CFU/mL within just 20 minutes, eliminating the need for time-consuming enrichment processes, hazardous reagents, or laboratory settings. By utilizing standard sampling methods and low-cost supplies, NanoSpy's technology allows for quick and accurate results, thereby enhancing safety testing for researchers and streamlining the detection process. This innovative approach represents a significant advancement in the field of pathogen detection.

Serinus Labs, Inc. is a manufacturer of nano-scale silicon gas sensors, established in 2017 and located in Berkeley, California. The company specializes in developing integrated chip-scale gas sensors tailored for various industries, including health and safety, automotive, consumer electronics, and healthcare. Serinus Labs offers custom solutions for both established and emerging gas sensor markets, focusing on applications such as Li-ion battery state-of-health monitoring. Their ultra-low-power trace gas sensors contribute to enhancing battery intelligence, particularly in electric vehicles, addressing critical needs in strategic markets.

Samay is a developer of an AI-enabled wearable device focused on remote respiratory health management, specifically targeting chronic obstructive pulmonary disease (COPD). The company's innovative chest patches utilize patented technology to diagnose COPD with 90% accuracy and identify exacerbation biomarkers at 83% accuracy, all while allowing patients to remain at home. The device continuously monitors various respiratory metrics, including pulmonary volumes, trapped air, respiratory and heart rates, breathing sounds, and temperature for up to two weeks. This real-time data collection empowers users to analyze their respiratory health and receive actionable insights to enhance their day-to-day well-being. Additionally, Samay is creating an AI-assisted management and diagnostic platform that supports both patients and doctors throughout the care continuum, from detecting exacerbations to determining effective therapies for more personalized treatment.

Frugi Biotechnology is a synthetic biology company based in Ames, Iowa, founded in 2020. The company specializes in developing modular, paper-based diagnostics aimed at managing viral outbreaks. Frugi's services include creating custom cell-free extracts that facilitate the building and testing of learn cycles for clients involved in protein biomanufacturing and protein discovery. This allows clients to detect pathogens in a simplified and cost-effective manner, enhancing the capabilities for outbreak management and response.

HC Simulation, founded in 2011 and headquartered in Canton, Mississippi, focuses on developing advanced products that utilize the HumMod engine to simulate human physiology. The company's offerings allow users to explore physiological interactions that are often difficult to observe through traditional methods. By providing high-quality simulations, HC Simulation aids in the ideation, development, and prediction of innovative medical devices and pharmaceuticals, enhancing the understanding of complex biological systems.

Innsightful offers a comprehensive digital health solution aimed at managing and alleviating mental health challenges, particularly for students. The company develops wearable devices that monitor and detect symptoms of anxiety and stress, utilizing artificial intelligence and machine learning to provide automated, early detection of heightened stress levels. These devices integrate biometrics to give users personalized insights, fostering a deeper understanding of their mental health. Additionally, Innsightful facilitates access to therapists for tailored recommendations and progress assessments, transforming how individuals approach their mental well-being.

NeuroTechR3 is a biomedical device and digital health start-up that focuses on developing affordable rehabilitation technologies to enhance upper extremity function for individuals affected by brain injuries, including stroke and cerebral palsy. The company's flagship innovation, R3THATM, leverages machine learning and cloud technology to enable personalized telerehabilitation through engaging exergames designed to foster neuroplasticity. This system includes features such as motion tracking, analytics, and real-time biofeedback, which help clinicians provide high-quality, efficient care while improving patient recovery outcomes. Founded in 2020 by a team of four women, NeuroTechR3 emerged from the New Jersey Institute of Technology and Rutgers University, and operates from locations in Newark, NJ, and Philadelphia, PA. The company's expertise lies in biomedical engineering and computer science, positioning it to address the needs of the rehabilitation industry effectively. By advancing rehabilitation devices and machine learning-driven technologies, NeuroTechR3 aims to transform healthcare and make rehabilitation more accessible and sustainable for individuals with various impairments.

Kinetica Labs is a company based in Ann Arbor, Michigan, specializing in sensing and simulation technology. It provides innovative Motion Capture technology that transforms video footage into precise posture data, enabling the assessment of ergonomic risks in the workplace without relying on markers, suits, or sensors. In addition to its core technology, Kinetica Labs offers a range of services including insurance consultancy, safety audits, ergonomic assessments, and physical therapy services, catering to clients seeking to enhance workplace safety and employee well-being.

LiteraSeed operates a clinically validated digital health platform designed to enhance communication between healthcare providers and low health literate patient populations. The platform addresses significant challenges faced by public health providers, particularly in serving patients who may not speak English or have other communication barriers. By enabling these individuals to accurately and remotely self-report symptoms, LiteraSeed aims to prevent costly misdiagnoses, adverse events, and unnecessary emergency room admissions. This approach not only improves access to care for disadvantaged patients but also makes clinical encounters more productive, fostering better understanding of health status and overall patient outcomes.

EndoShunt Medical, founded in 2022 and based in Nashville, Tennessee, specializes in developing a medical device aimed at targeted hemorrhage control in emergency situations. The company's innovative device facilitates endovascular shunting of blood past hemorrhaging vessels, allowing surgeons to perform definitive repairs while maintaining blood flow. This technology is designed to enhance outcomes in critical care scenarios, addressing the urgent need for effective solutions in managing severe bleeding.

Alva Health specializes in the development of healthcare wearables focused on remote stroke monitoring. The company's patented devices operate continuously to detect stroke signatures, specifically identifying the onset of hemiparesis, or paralysis on one side of the body. By connecting users to emergency services, Alva Health's technology aims to empower older adults at high risk of stroke, facilitating early intervention to prevent disability. The company is committed to transforming stroke treatment and advancing neurotechnologies that enhance patient safety and independence, ultimately providing peace of mind for families.

The Natural Nipple specializes in the development of innovative feeding bottles that enhance the breastfeeding experience for mothers and their babies. Their products are designed to closely mimic the shape of the natural breast and replicate the maternal flow rate of breast milk, helping to eliminate nipple confusion. This allows infants to transition smoothly between bottle and breast, addressing a common challenge for breastfeeding mothers. By facilitating this transition, The Natural Nipple aims to support improved mother-baby health and bonding, while also promoting protective neurological development through the establishment of a healthy microbiome. This approach seeks to prevent long-term issues associated with gut bacterial dysbiosis.

InGateyGen is an agricultural biotechnology company focused on developing and producing hypoallergenic or allergen-reduced peanuts. Utilizing proprietary technologies such as genomics, proteomics, plant tissue culture, and plant propagation, the company aims to create high-value agricultural products that enhance consumer safety and well-being. InGateyGen's commitment to innovation in food science seeks to address the growing demand for allergen-free options, ultimately contributing to improved health outcomes for individuals with peanut allergies.

Precision Theranostics is a biotechnology company based in Baltimore, Maryland, founded in 2019. The company focuses on developing prognosis-based intervention strategies aimed at the early detection and treatment of fatal diseases. Its innovative platform is designed to estimate disease progression, particularly for respiratory diseases and age-related disorders. By creating novel diagnostics, therapeutics, and prognosis-based therapies, Precision Theranostics enables healthcare providers to deliver timely diagnoses and interventions, ultimately improving survival rates and preventing the progression of chronic and fatal conditions.

CellDrop Biosciences, established in 2017 and based in Laramie, Wyoming, specializes in hydrogel-based technology for point-of-care diagnostics and targeted biomaterial delivery. The company focuses on developing hydrogel platforms that enable precise control over chemical and biological systems. Its innovations aim to facilitate the healing of equine musculoskeletal injuries efficiently, while also minimizing the risk of re-injury. By providing effective diagnostic and treatment solutions, CellDrop Biosciences addresses critical needs within the veterinary medical community.

HealthTrends.AI is a provider of an AI and blockchain-based platform that focuses on enhancing the accessibility and trustworthiness of public health data. The company aims to assist organizations in converting health data into actionable insights through its innovative solutions. Its offerings include standard APIs, predictive analytics, and comprehensive analysis reports, which facilitate the management of finance, supply chain, logistics, and patient engagement for healthcare providers. HealthTrends.AI's products are available as streaming feeds, dashboards, and other formats, allowing for seamless integration with third-party tools such as Power BI and Tableau. The platform is designed to be user-friendly and complements existing systems, making authoritative health information readily accessible and independently auditable.

NeuroTechR3 is a biomedical device and digital health start-up that focuses on developing affordable rehabilitation technologies to enhance upper extremity function for individuals affected by brain injuries, including stroke and cerebral palsy. The company's flagship innovation, R3THATM, leverages machine learning and cloud technology to enable personalized telerehabilitation through engaging exergames designed to foster neuroplasticity. This system includes features such as motion tracking, analytics, and real-time biofeedback, which help clinicians provide high-quality, efficient care while improving patient recovery outcomes. Founded in 2020 by a team of four women, NeuroTechR3 emerged from the New Jersey Institute of Technology and Rutgers University, and operates from locations in Newark, NJ, and Philadelphia, PA. The company's expertise lies in biomedical engineering and computer science, positioning it to address the needs of the rehabilitation industry effectively. By advancing rehabilitation devices and machine learning-driven technologies, NeuroTechR3 aims to transform healthcare and make rehabilitation more accessible and sustainable for individuals with various impairments.

Radiosight, founded in 2020 and headquartered in Hoboken, New Jersey, specializes in ultra-wide imaging technology aimed at improving the diagnosis of skin cancer and assisting in surgical decisions. The company has developed an innovative technique that enhances image resolutions, offering a handheld 3D imaging device that reveals the underlying shape and profile of suspicious tissue. This technology enables dermatologists to better visualize the margins before biopsy, thereby increasing the accuracy of skin lesion excisions. Through its advanced imaging solutions, Radiosight seeks to enhance the effectiveness of skin cancer treatment and diagnosis.

SweatID is a developer of wearable fabric sensors designed for health and fitness applications. Their sensors help to monitor hydration on the surface of the skin in real time, enabling users to continuously monitor biomarkers.

Abram’s is a novel diagnostic platform for diagnosis and characterization of coagulation-related disorders, delivering rapid hemostasis information to improve clinical outcomes.

Cobio Diagnostics is a biotechnology company based in Golden, Colorado, founded in 2016. The company specializes in developing diagnostics aimed at rapid bacterial identification and phenotypic antibiotic resistance testing. Utilizing a phage-based immunoassay, Cobio Diagnostics' technology can identify specific bacterial species and determine the most effective antibiotic treatment in under five hours. This innovative approach provides a faster and more targeted alternative to traditional diagnostic methods, allowing healthcare providers to make quicker and more informed decisions regarding antibiotic treatment for patients with bacterial infections.

Quick-Med Technologies, Inc. is a life sciences company dedicated to developing proprietary technologies aimed at infection prevention and control in both medical and consumer healthcare markets. Founded in 1997 and headquartered in Gainesville, Florida, the company specializes in biomedical products and devices with antibacterial applications. Its core technologies include Novel Intrinsically Micro-Bonded Utility Substrate (NIMBUS), a series of advanced polymers with antimicrobial and hemostatic properties; Stay Fresh, a chemical formulation for textiles that provides durable antimicrobial protection; and MultiStat, which comprises patented methods and compounds for skin therapy. Quick-Med serves a diverse range of clients, including government agencies, healthcare providers, and companies in the apparel, textile, and personal care sectors.

OmniVis is a biotechnology company that has created an integrated portable platform for the detection of pathogens in various environments, including food processing facilities. The company offers a handheld device that quantitatively measures pathogens, providing accurate results in under 30 minutes. This technology utilizes single-use disposable test kits that analyze swabs or liquid samples, significantly reducing the time and labor associated with traditional lab testing. By delivering a low-cost and user-friendly solution, OmniVis enables health organizations to enhance their pathogen detection capabilities effectively.

PediaMetrix Inc. is a company focused on developing innovative digital solutions for pediatric head measurement and monitoring. Founded in 2018 by alumni from Johns Hopkins, NIH, and Oxford, the company is based in Rockville, Maryland. Its primary product, SoftSpot, is a mobile application that leverages artificial intelligence and computer vision to provide accurate measurements of infants' head shapes. This app allows parents to receive personalized repositioning instructions and enables pediatricians to access easy-to-understand data analysis, facilitating timely and effective care. By focusing on early detection and management of head shape abnormalities, PediaMetrix aims to enhance healthcare outcomes and reduce costs associated with pediatric care.

Spatio Metrics offers a design analytics platform aimed at enhancing health outcomes through improved architectural design in healthcare facilities. By analyzing floor plans, the platform identifies design gaps and suggests performance improvements, enabling hospital administrators to make informed design investments. It bridges the divide between design, data, and human performance by leveraging computational analysis of spatial characteristics and trends. This approach integrates previously disconnected data sources, fostering collaboration among teams and allowing clients to test ideas and prioritize interventions. Ultimately, Spatio Metrics seeks to increase operational efficiency and enhance patient well-being by quantifying the effects of design on health outcomes.

NeuroDyne specializes in developing medical technology aimed at diagnosing and treating neurological diseases. The company focuses on creating devices that alleviate seizure activity in children with congenital brain disorders, adults experiencing seizures, and veterans affected by brain damage. By providing innovative solutions, NeuroDyne enables medical professionals to offer effective relief to individuals suffering from the debilitating effects of seizures.

Vena Vitals is a company that develops a small wearable device designed for continuous blood pressure monitoring. This innovative technology has shown accuracy comparable to invasive arterial lines in clinical settings such as operating rooms and intensive care units. By focusing on applications in the healthcare sector, Vena Vitals aims to enhance the management and monitoring of blood pressure, which is crucial for individuals with hypertension and other cardiovascular conditions. The company's platform has the potential to significantly improve the quality of care provided to patients, making it a valuable asset in clinical environments where blood pressure data is essential.

Blueshift Optics specializes in the development of advanced organic scintillator technology, focusing on enhancing radiation detection capabilities. Their innovative scintillator materials are designed to offer superior neutron detection and high gamma discrimination, making them suitable for a variety of applications within the radiation detection community. By prioritizing quality performance, Blueshift Optics aims to provide physicists with efficient organic glass scintillators that meet diverse detection needs.

BioAesthetics LLC, founded in 2015 as a spin-out from Tulane University, is focused on developing innovative reconstruction options for breast cancer patients following mastectomies. The company specializes in a tissue-engineered nipple-areolar complex (NAC) that serves as an acellular graft to be used by plastic and reconstructive surgeons during the breast reconstruction phase. This product allows the patient's own cells to integrate with the graft, facilitating the regeneration of a natural nipple and areola. Currently in the pre-clinical phase, this patent-pending technology aims to provide a more effective and aesthetically pleasing solution for patients who have experienced incomplete or removed NACs due to illness, surgery, or congenital conditions. BioAesthetics is headquartered in Research Triangle Park, North Carolina.

BiomeSense, Inc. is a company that specializes in developing an integrated platform combining hardware, software, and data analytics to enhance the collection and analysis of microbiome data in clinical research. Founded in 2018 and based in Chicago, Illinois, BiomeSense has created the GutLab, an innovative "smart bathroom" system designed for continuous, at-home monitoring of the human gut microbiome. This technology, along with the MetaBiome time-series analytics platform, provides a comprehensive solution that enables researchers, patients, and consumers to track microbiome changes in real time and understand their impact on health outcomes. By generating and analyzing large-scale, longitudinal microbiome datasets, BiomeSense aims to discover and commercialize novel microbiome biomarkers, ultimately improving precision medicine and the development of microbiome-based therapeutics and products.

Nextiles is a New York-based company founded in 2019 that specializes in smart apparel technology, merging athletic clothing with an advanced analytics system to enhance exercise performance and safety. The company innovatively integrates electrically conductive fibers into fabrics using a patented sewing technology, allowing for the development of wearables that include motion sensors directly within the apparel. This unique approach enables the creation of responsive and adaptive devices, providing valuable insights into an individual's movement patterns. With a strong foundation in electrical engineering and circuit design, Nextiles offers its expertise to businesses looking to develop or enhance their own Internet of Things (IoT) and smart device products.

Lasarrus is a Baltimore-based company founded in 2013 that specializes in developing wearable devices for patients with chronic obstructive pulmonary disease (COPD). The company's innovative device is designed to enhance physical therapy by facilitating telemedicine and remote monitoring. It captures physiological and range-of-motion data, allowing patients to track their health routines effectively. Lasarrus aims to provide an affordable, comfortable, and non-invasive solution that accelerates recovery for users, improving their overall health management.

Inanovate Inc. specializes in developing protein screening and analysis products for the life sciences sector. The company offers the Bio-ID platform, a protein screening biochip that provides real-time, sensitive kinetic data on multiple protein interactions. This technology is applicable in various areas, including protein research, drug development, quality control, biomarker profiling, validation, and clinical diagnostics. Inanovate also provides biomarker alliance programs, i-Slide nano-particle surface technology for protein immobilization, and a range of protein micro-array services, such as assay development and support. The company serves researchers, clinical centers, and biotech and pharmaceutical firms. Founded in 2006 and headquartered in Sioux Falls, South Dakota, Inanovate has an additional office in Raleigh, North Carolina, and operates in the United States and the United Kingdom.

NanoInnovations is a research and development company established in 2014 and based in Sugar Land, Texas. It focuses on the commercialization of smart nanosensors integrated with machine learning technologies for healthcare analytics. The company's innovative platform utilizes bio-fluids, including sweat and saliva, to provide valuable insights for managing conditions such as diabetes and heart failure. By delivering real-time information, NanoInnovations aims to enhance patient care and improve healthcare management, empowering clients to make informed decisions in their medical practices.

OmnEcoil Instruments is a Portland, Oregon-based company founded in 2016 that focuses on developing an innovative device for the detection of prostate cancer and tissue sampling. The device enhances the traditional ultrasound-guided prostate biopsy approach by integrating MRI technology, allowing for a more efficient and accurate diagnostic procedure. This advancement aims to improve the quality of care for patients by providing healthcare providers with a streamlined method for identifying prostate cancer and obtaining tissue samples.

Novonate is a healthcare technology company focused on improving neonatal care through innovative medical devices. The company's flagship product, LifeBubble, enhances the safety of vascular catheter management in neonatal intensive care units. By providing stronger securement for umbilical catheters, LifeBubble minimizes the risks of catheter migration and premature discontinuation, which are critical concerns in neonatal settings. This device is designed to protect the umbilical catheter insertion site from complications associated with central lines, thereby ensuring safer and more stable care for vulnerable infants during medical procedures such as phlebotomy.

Starling Medical focuses on creating a remote patient monitoring platform that facilitates at-home urine diagnostics, integrating seamlessly into everyday bathroom routines. The company is developing a healthcare device that employs mass spectroscopy-based sensors to continuously monitor changes in urine composition. This technology aims to enable early detection of chronic health issues, allowing both patients and healthcare providers to intervene promptly and potentially prevent serious complications or hospitalizations. By offering predictive insights, Starling Medical aspires to enhance health outcomes through proactive monitoring.

Claria Medical is a pre-commercial medical device start-up focused on developing innovative solutions for women's healthcare, specifically targeting unmet needs in gynecologic surgery. The company specializes in creating minimally invasive surgical tools designed to enhance procedures such as hysterectomy and myomectomy. Claria Medical has received recognition for its early achievements, including a “Safer Technologies Designation” from the U.S. Food and Drug Administration. Additionally, the company has secured funding through private investments as well as grants from the National Science Foundation and the National Institutes of Health to support its product development efforts. By providing specialized surgical assistance, Claria Medical aims to improve outcomes for women undergoing these procedures.

Ionica Sciences, Inc. is focused on developing a spectroscopy-based diagnostic platform that utilizes surface enhanced Raman scattering (SERS) technology. Founded in 2013 and headquartered in Ithaca, New York, the company aims to address urgent needs in clinical diagnostics by enabling rapid and accurate identification of vector-borne, sexually transmitted, and neurological diseases. Ionica Sciences is particularly dedicated to creating in-vitro diagnostic assays for Lyme disease and other infectious conditions, allowing medical professionals to detect biologically relevant targets such as pathogens and hormones. By improving diagnostic accuracy, the company seeks to reduce patient suffering, minimize unnecessary antibiotic use, and lower healthcare costs associated with misdiagnoses.

Flotherm is a company based in Los Angeles, California, that specializes in the development of a thermal compression device aimed at maintaining normothermia during surgical procedures. This innovative device is designed to provide perioperative warming without obstructing access to the surgical site or increasing the risk of contamination. By integrating dynamic compression with lower-limb warming, Flotherm's technology allows surgeons to effectively manage the risks associated with accidental hypothermia and deep-vein thrombosis. The device enhances perioperative compliance while seamlessly fitting into existing surgical workflows.

FloBio specializes in point-of-care diagnostics focused on assessing bleeding risk through real-time blood analysis. Founded in 2017 and based in Philadelphia, PA, the company has developed an innovative fluidic-based diagnostic platform that utilizes microfluidic technology. This platform allows for rapid and precise measurements of blood clotting function under physiological conditions, enabling clinicians to make informed decisions and personalize patient management swiftly during critical situations.

HabitAware, Inc. is a company that develops and sells wearable devices aimed at helping individuals manage subconscious behaviors such as hair pulling, nail biting, skin picking, and thumb sucking. Its flagship product, Liv, is a smart awareness bracelet equipped with motion sensors that alerts users when they engage in these habits. The accompanying Liv application provides training to help users recognize their problematic behaviors, track their progress, identify triggers, and offers strategies for replacing these habits with healthier alternatives. Founded in 2014 and headquartered in Minneapolis, Minnesota, HabitAware focuses on supporting both children and adults in gaining control over their compulsive behaviors. The company sells its products online, making its resources accessible to a wide audience.

Plexision develops cellular biomarkers for personalized diagnosis and drug development in solid organ transplantation, and immunological disorders. Plexision's first patented product, the PleximmuneTM assay, predicts the risk of transplant rejection. The test is based on patent-pending technology to measure antigen-specific white blood cells. Testing services for transplant recipients and drug developers are provided at Plexision’s CLIA-certified, central laboratory in Pittsburgh. Plexision currently offers cell-based testing for personalized assessment of rejection risk after solid organ transplantation The Pleximmune blood test is the first such test offered for children with liver or intestine transplantation.

RoboPath specializes in robotics and artificial intelligence for the pathology industry. The company was founded in 2019 and is headquartered in Leawood, Kansas.

Lumedica specializes in developing low-cost, high-performance Optical Coherence Tomography (OCT) imaging technologies. The company is focused on bringing its first fully patented OCT device to market, which aims to enhance the monitoring and detection of eye diseases by providing detailed imaging of the retina and related structures. Lumedica's technology leverages advanced optical components to improve eye imaging capabilities, allowing eye specialists to identify abnormalities and monitor minute changes in the eye effectively. The firm has a strong background in scientific innovation and product development and is currently supported by grants from the National Institutes of Health and the State of North Carolina.

Avisi Technologies Inc. is a company based in Philadelphia, Pennsylvania, that focuses on developing innovative solutions for glaucoma treatment. Founded in 2017, the company has created VisiPlate, a next-generation aqueous shunt that utilizes nanotechnology to provide a defense against blindness caused by glaucoma. This advanced technology aims to improve the effectiveness of glaucoma treatments and enhance patient outcomes.